Understanding of latent tuberculosis, its treatment and treatment side effects in immigrant and refugee patients by Katie Butcher et al.
Butcher et al. BMC Research Notes 2013, 6:342
http://www.biomedcentral.com/1756-0500/6/342RESEARCH ARTICLE Open AccessUnderstanding of latent tuberculosis, its
treatment and treatment side effects in
immigrant and refugee patients
Katie Butcher1, Beverley-Ann Biggs1,2, Karin Leder2,3, Chris Lemoh1,2, Daniel O’Brien2,4 and Caroline Marshall1,2*Abstract
Background: Isoniazid treatment of latent tuberculosis infection (LTBI) is commonly prescribed in refugees and
immigrants. We aimed to assess understanding of information provided about LTBI, its treatment and potential
side effects.
Methods: A questionnaire was administered in clinics at a tertiary hospital. Total Knowledge (TKS) and Total Side
Effect Scores (TSES) were derived. Logistic regression analyses were employed to correlate socio-demographic
factors with knowledge.
Results: Fifty-two participants were recruited, 20 at isoniazid commencement and 32 already on isoniazid. The
average TKS were 5.04/9 and 6.23/9 respectively and were significantly associated with interpreter use.
Approximately half did not know how tuberculosis was transmitted. The average TSES were 5.0/7 and 3.5/7
respectively, but were not influenced by socio-demographic factors.
Conclusions: There was suboptimal knowledge about LTBI. Improvements in health messages delivered via
interpreters and additional methods of distributing information need to be developed for this patient population.
Keywords: Latent tuberculosis infection, Health literacy, Immigrant, RefugeeBackground
The global epidemiology of tuberculosis (TB) is signifi-
cantly influenced by human migration. Immigrants from
TB endemic nations continue to have TB rates that mirror
their country of origin and account for a large proportion
of active TB cases in industrialised nations [1-7]. In
Australia the incidence of TB in 2009 was 6.4 per 100,000
people [8]. There is incomplete information about the rate
amongst refugees and immigrants from high prevalence
nations but studies have shown this to be higher than the
general Australian population [4,9,10].
The majority of Mycobacterium tuberculosis infections
do not result in active disease. In greater than 90% of
cases the individual remains asymptomatic and non-
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reproduction in any medium, provided the or(LTBI) [11-14]. LTBI may progress to active disease and
therefore potentially poses a major public health prob-
lem, especially in individuals infected with HIV. LTBI ac-
quired prior to migration may reactivate after settlement
in a new country. Effective diagnosis and treatment of
LTBI are integral to TB prevention and control in devel-
oped nations. The American Thoracic Society and the
Centers for Disease Control and Prevention recom-
mends several regimens for treatment of LTBI. The regi-
men most commonly used in Australia is 300 mg
isoniazid once daily for nine months, which reduces the
risk of active disease by approximately 80% [15]. Other
less commonly used options include shorter, rifampicin-
containing regimens. Isoniazid has been linked with ser-
ious side effects, the most severe being hepatotoxicity,
so careful monitoring is needed [15,16]. Adherence may
be variable, largely due to the lengthy treatment dur-
ation, lack of disease symptoms and potential adverse
events [17-20]. It is thereby essential that patients on
isoniazid are thoroughly informed about the treatmentl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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cation regimen and the symptoms that may indicate ser-
ious side effects.
Immigrant and refugee patients often have low health
literacy, posing challenges for health education [14].
Many refugees come from low socio-economic, non-
English speaking backgrounds or have limited education
and poor knowledge of health and health services.
Inadequate health literacy along with language barriers
and different cultural and religious beliefs have been as-
sociated with lower adherence levels amongst these pa-
tients on isoniazid for LTBI [13,18,19,21-24].
In Victoria, patients requiring assessment and man-
agement of LTBI are usually referred by their general
practitioner to infectious diseases clinics at tertiary
hospitals. The Victorian Infectious Diseases Service
(VIDS) at the Royal Melbourne Hospital (RMH) as-
sesses large numbers of immigrants and refugees with
active TB and LTBI at two clinics, the immigrant and
refugee clinic and the TB clinic. Those attending the
immigrant and refugee clinic are usually refugees or
asylum seekers, who are often recently arrived and may
have several medical problems. The patients attending
the TB clinic tend to have a single problem and are
more likely to be migrants. Currently, treating physi-
cians educate patients about LTBI, isoniazid treatment
and possible side effects. However, it is not known to
what extent patients understand or remember infor-
mation they have been given and whether this is in-
fluenced by education, ethnicity or gender. Anecdotal
reports suggest that patients sometimes take medica-
tion incorrectly and forget important potential side ef-
fects. The objectives of this study were firstly, to assess
refugee and immigrant patients’ knowledge and under-
standing of information given about LTBI, the treat-
ment regimen and potential side effects of isoniazid
and secondly, to evaluate whether demographic factors
were associated with knowledge and understanding in
order to determine if better methods of providing in-
formation are required.
Methods
Study design and data collection
RMH is a university-affiliated, tertiary referral hospital. A
convenience sample of patients attending the immigrant/
refugee and the TB clinics between May 5th and October
9th 2009 was recruited, consisting of patients referred spe-
cifically because of a positive QuantiFERON®-TB Gold
(Cellestis Ltd, Carnegie, Victoria, Australia) or tuberculin
skin test (1 ml of a 100 IU PPD solution [CSL] injected
intra-dermally). We intended to recruit at least 50 partici-
pants, based on what we perceived would give a reason-
able indication of patient knowledge and what was feasible
given the available personnel and time frame.Patients diagnosed with LTBI were included if they
were commencing or already taking isoniazid therapy
for LTBI, were born in a country with a high prevalence
of TB and had lived in Australia for less than ten years.
We reviewed all histories of patients booked into each
clinic to try to capture all potential participants. Ap-
proximately 55 patients newly commenced isoniazid
during the study period, although we do not have de-
nominator figures for those already on isoniazid. We did
not favor or exclude on specific country of birth or lan-
guage criteria, but there needed to be clinic space and
both interviewer and interpreter time available after (See
Additional file 1) or before (See Additional file 2) the
patient appointment in order to make it feasible to con-
duct the interview.
Usual clinical management of LTBI at VIDS includes a
detailed verbal explanation about LTBI and the isoniazid
treatment regimen given by the treating physician at the
initial consultation prior to commencement of treat-
ment. Interpreters are used at every visit where neces-
sary (including follow-up visits), although occasionally
this may be via the telephone interpreter service. On
most occasions, qualified interpreters are used, but there
is no requirement for them to be qualified in medical
terminology. Rarely, family members or friends are used
as interpreters if there is no trained interpreter available.
Commencement of isoniazid therapy would usually be
deferred if there is no suitable interpreter available.
Written information is available in English and some
of the other languages spoken by our patients, but is not
always given to patients. The potential side effects of iso-
niazid are verbally described by the doctor, as is the
course of action to take if these occur. Patients opting
for treatment are usually given nine months of daily iso-
niazid. Alternative rifampicin-containing regimens are
rarely used in our clinic. Pyridoxine is sometimes also
prescribed [15]. Patients over the age of 35 are not usu-
ally offered isoniazid therapy because of the potential for
age related hepatotoxicity [15]. Patients on isoniazid are
always assessed after one month of treatment and then
at one to three month intervals over the treatment
course, depending on other co-morbidities and perceived
need by treating physician. Liver function is tested at
baseline but not routinely thereafter, unless the patient
reports symptoms suggestive of hepatotoxicity. Educa-
tion would usually be given by the treating physician at
each visit depending on perceived need.
Two questionnaires were designed specifically for this
study (See Additional file 1 and Additional file 2). We
found no other published questionnaires covering areas
that were of interest to the authors and none that had
been administered to refugee patients. We pilot tested
the questionnaires on nine patients over a two week
period, resulting only in minor changes to the structure
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cluded in the analysis.
Questionnaire 1 contained 23 questions consisting of
eight socio-demographic questions and 15 to assess
knowledge and understanding of LTBI, isoniazid regi-
men and side effects. It was administered to patients at
the initial consultation when isoniazid treatment was
first prescribed. The questionnaire was completed fol-
lowing the consultation to assess immediate recall of in-
formation provided by the doctor.
Questionnaire 2 consisted of the same questions as
Questionnaire 1 with three additional questions regard-
ing the number of missed days of isoniazid and whether
the diagnosis had affected either the patient or their
family’s daily lives. It was administered to assess long
term recall at a follow-up consultation after participants
had been taking isoniazid for at least one month. Ques-
tionnaire 2 was administered prior to the patient seeing
the doctor on these follow-up visits. Where possible,
participants completed both Questionnaire 1 and Ques-
tionnaire 2. Questionnaires were read aloud to partici-
pants, through the use of an interpreter if necessary.
Data analysis
A “Total Knowledge Score” (TKS) was calculated for
each participant by adding the score from five questions
that were deemed (by consensus from the physicians in
the clinic) to be the best indicators of overall LTBI
knowledge, the treatment regimen and isoniazid side ef-
fects (including elements from questions 9, 10, 15, 19
and 20 see Additional file 2). Participants were awarded
two points for knowing they had LTBI and one point for
a reference to TB. Two points were given if the partici-
pant mentioned they were taking the same medication
as prescribed and one point if they didn’t distinguish be-
tween INH and pyridoxine. Knowing TB was spread via
some form of microbe, that nausea/vomiting, abdominal
pain or jaundice were side effects of INH and mention-
ing to stop medication if side effects occurred were
awarded one point each giving a Total Knowledge Score
out of nine. Binary TKS categories of high (>6) and low
(≤6) were created as the outcome variable for regression
models. Higher TKS indicated better results. Predictors
of high TKS score were analysed using univariable and
multivariable Poisson regression with robust standard
errors. A Poisson approach was preferred over logistic
modeling secondary to the relative frequency of the out-
come variable (high TKS score was recorded for 48% of
the sample). Poisson modeling also permitted direct cal-
culation of relative risk whereas a logistic approach, in
light of the frequency, would likely have returned over-
estimates of relative risk. Candidate predictors for inclu-
sion in the multivariable model were identified as those
considered to be clinically important by the researcherscoupled with performance on univariable modeling. The
number of outcomes (n = 22) limited adjusted modeling to
a maximum of two concurrent explanatory variables to
avoid over-fitting of the data. Collinearity between pre-
dictor variables was tested for. Interactions between pre-
dictors, as distinct from collinearity were examined using
a likelihood-ratio test. Overall goodness of fit of the
Poisson models was assessed using a Poisson chi-square
goodness of fit test. Competing multivariable Poisson
model solutions were compared using a bias-corrected
Akaike Information Criterion [25] to identify the most
parsimonious combination of predictor variables that was
consistent with clinical expectations.
A “Total Side Effect Score” (TSES) was also generated
by awarding one point for each of the seven potential
side effects of isoniazid remembered by the participant
(liver problems, nausea/vomiting, abdominal pain, jaun-
dice, nerve problems, tingling/numbness in extremities
and rash). Higher TSES indicated better results.
Data were analyzed using Microsoft Excel™ 2003 and
STATA version 10 (StataCorp, College Station, TX). Re-
sults were considered statistically significant if the p-
value was <0.05 and all reported confidence intervals are
at 95%.
Ethics approval
This study was approved by the Melbourne Health Hu-
man Research Ethics Committee Quality Assurance
Stream. Verbal consent was obtained from all participants.
Results
Profile of study participants
Fifty-three patients were asked to take part in the study, of
whom 52 agreed to participate. Thirty-two had already
commenced isoniazid treatment and completed Ques1-
tionnaire 2 at a follow-up consultation. Twenty partici-
pants started on isoniazid during the study and completed
Questionnaire 1 at their initial consultation. Of these, 14
completed Questionnaire 2 at a subsequent consultation,
giving a total of 46 participants completing Questionnaire
2. Therefore, 20 patients completed Questionnaire 1, 46
completed Questionnaire 2 and 14 completed both.
Table 1 shows the socio-demographic characteristics
of study participants. Participants came from 18 differ-
ent countries (most commonly India, Ethiopia and
Burma) and spoke 16 different primary languages (most
commonly English and Nepalese). Twenty-two patients
required interpreters, who were available for all consul-
tations. Languages included Amharic, Arabic, Burmese,
Chin Hakka, Hindi, Karen, Korean, Oromo, Swahili, So-
mali and Vietnamese. Questionnaires were translated
directly to the participants. Fifteen participants were
born in sub-Saharan Africa, 17 in Asia, 18 in the Indian
sub-continent and 2 in the Middle East. Thirty-two
Table 1 Socio-demographic characteristics of study participants
Population
characteristics
Tertiary educated Not tertiary educated Total
(N = 32) (N = 20) (N = 52 a)
n (%) n (%) n (%)
Clinic
Refugee & Immigrant 4 (21.0) 15 (79.0) 19 (36.5)
TB 28 (84.9) 5 (15.1) 33 (63.5)
Gender
Male 14 (60.9) 9 (39.1) 23 (44.2)
Female 18 (62.1) 11 (37.9) 29 (55.7)
Interpreter Required
Yes 6 (27.3) 16 (72.7) 22 (42.3)
No 26 (86.7) 4 (13.3) 30 (57.7)
Reads English
Yes 32 (71.1) 13 (28.9) 45 (86.5)
No 0 7 (100) 7 (13.5)
Lived in a Refugee Camp
Yes 2 (20.0) 8 (80.0) 10 (19.2)
No 30 (71.4) 12 (28.6) 42 (80.7)
Time in Australia
< 6 months 2 (28.6) 5 (71.4) 7 (13.5)
6 months- < 1 year 11 (57.9) 8 (42.1) 19 (36.4)
1- < 5 years 15 (68.2) 7 (31.8) 22 (42.3)
5-10 years 4 (100.0) 0 4 (7.7)
Born in sub-Saharan Africa
Yes 5 (33.3) 10 (66.7) 15 (28.8)
No 27 (72.9) 10 (27.1) 37 (71.2)
Age (years)
Mean 28.0 27.9 27.9
Median 28 28 27.5
Range 18-37 18-36 18-37
a Total number of patients in study.
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while two had no formal education at all.
Participant understanding of latent tuberculosis
and treatment
The average TKS for Questionnaire 1 was 5.04 ± 2.50
(range 1–8) out of a total of nine. The average TKS for
Questionnaire 2 was 6.23 ± 1.80 (range 3–9). Only three
participants got the maximum score of nine (15%).
Seventy-five per cent (n = 15) of those who completed
Questionnaire 1 and 89% (n = 41) of participants who
completed Questionnaire 2 understood they had LTBI.
Typical correct responses were “non-active TB”, “non-ser-
ious TB” or “sleeping TB”. Responses to both Question-
naires 1 and 2 showed over 90% of participants knew that
LTBI was asymptomatic and non-transmissible (Table 2).There was a range of misconceptions about how TB was
spread including via water, dust, wind or pollution.
There was good understanding of the treatment regi-
men; the reported medication dose matched that pre-
scribed in 91.3% (n = 42) of participants who completed
Questionnaire 2. However, 37.0% (n = 17) of participants
stated they had missed 1–5 days of medication in the
past month, with “forgetting” being the most common
reason (Table 2).
Participant understanding of isoniazid side effects
The mean TSES for participants completing Question-
naires 1 and 2 was 5.0 ± 1.8 (range 2–7) and 3.5 ± 1.8
(range 0–7) respectively. Only two participants who com-
pleted Questionnaire 2 could mention all seven side ef-
fects and two could not recall any (Table 3). Participants




Questionnaire 1 Questionnaire 2
(N = 20 a) (N = 46 b)
n (%) n (%)
Why are you coming to this clinic?
Knew they had LTBI 15 (75.0) 41 (89.1)
Couldn’t distinguish between TB &
LTBI
5 (25.0) 4 (8.7)
Unsure 0 (0.0) 1 (2.2)
What is TB caused by?
Knew it was caused by a
transmissible microbe
9 (45.0) 22 (47.8)
Unsure 11 (55.0) 24 (52.2)
Does this condition make you sick?
Yes 0 (0.0) 2 (4.4)
No 20 (100.0) 44 (95.7)
Can you give this condition to
anyone else?
Yes 1 (5.0) 1 (2.3)
No 18 (90.0) 43 (93.5)
Unsure 1 (5.0) 2 (4.4)
How will taking the tablets help you?
Reduce the risk of active TB in the
future
19 (95.0) 41 (89.1)
Unsure 1 (5.0) 5 (10.9)
How many tablets will/do you take a
day?
Answer same as medication
prescribed
14 (70.0) 42 (91.3)
Answer different to medication
prescribed
6 (30.0) 4 (8.7)
Do you know the name of the
tablets?
Yes 4 (20.0) 15 (32.6)
No 16 (80.0) 31 (67.4)
How many times a day will/do you
take the tablets?
Once 16 (80.0) 45 (97.8)
Three Times 0 (0.0) 1 (2.2)
Unsure 4 (20.0) 0 (0.0)
How long will you need to take the
tablets for?
9 months 16 (80.0) 35 (76.1)
6–9 months 4 (20.0) 7 (15.2)
6 months 0 (0.0) 3 (6.5)
Unsure 0 (0.0) 1 (2.2)
How many days of tablets have you
missed in the last months?
Table 2 Participant understanding of LTBI and
isoniazid treatment (Continued)
None N/A 25 (54.3)
1–5 days N/A 17 (37.0)
5–10 days N/A 4 (8.7)
LTBI = Latent Tuberculosis Infection; TB = Tuberculosis.
a 20 patients started on isoniazid and completed Questionnaire 1.
b 46 patients completed Questionnaire 2.
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such as dizziness, change in urine colour, night sweats,
acne and hair loss. All 46 participants who completed
Questionnaire 2 said they would contact a doctor should
they experience side effects and half said they would stop
taking isoniazid (n = 24, 52.2%).
Effect of socio-demographic determinants on
participant understanding
Results of the univariable and multivariable analyses sho-
wing predictor variables for TKS are shown in Table 4.
Having an interpreter during the consultation was a sig-
nificant predictor of a low TKS, in both univariable and
multivariable analysis on Questionnaire 2.
Discussion
This is the first Australian study to provide a snapshot
of the level of understanding about LTBI, isoniazid
treatment and its side effects amongst refugee and im-
migrant patients attending a tertiary referral hospital.
The study identified significant gaps with almost half
not knowing how TB was spread and many not able to
recall the side effects of isoniazid. The study identified
an association between the use of an interpreter and
having a low overall knowledge score. These findings
demonstrate a critical need for improved strategies for
the provision of health education to immigrant and
refugee patients receiving treatment for latent tubercu-
losis to ensure its effectiveness.
Many misconceptions about the way TB is spread were
reported. This finding is consistent with other studies
in different ethnic groups, indicating that cultural beliefs
may have a confounding influence on disease knowledge
[14,24,26]. Furthermore, misconceptions about the spread
of TB have previously been shown to impact upon an indi-
vidual’s willingness to take prophylactic medication and
compliance with isoniazid [19,21,23,26].
The incomplete understanding of isoniazid side effects
is similar to that found amongst Latino immigrants to
the US [14]. Limited recall of the potential side effects of
isoniazid amongst participants is concerning, most sig-
nificantly because of the hepatotoxicity risk. Immigrant
and refugee patients from non-English speaking back-
grounds may have particular trouble understanding the
complex side effects of isoniazid, especially if they have
Table 3 Potential isoniazid side effects reported by
participants who completed questionnaire 2
Participant responses
(N = 46 a)
Isoniazid side effect
Yes No
n (%) n (%)
Liver Problems 25 (54.3) 21 (45.7)
Nausea/ Vomiting 25 (54.3) 21 (45.7)
Abdominal Pain 26 (56.5) 20 (43.5)
Jaundice 21 (45.7) 25 (54.3)
Nerve Problems 19 (41.3) 27 (58.7)
Tingling/Numbness in extremities 24 (52.2) 22 (47.8)
Rash 23 (50.0) 23 (50.0)
a 46 participants completed Questionnaire 2.
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these side effects may not translate specifically into other
languages and the meaning may be difficult to convey.
Having an interpreter was significantly associated
with a 69% lower chance of having a high score after ad-
justment for clinic day. This finding has not been de-
scribed before in similar studies. It may indicate
inadequate training of interpreters with either lack of
knowledge of particular terms used in discussion of
LTBI or absence of such words in some languages, mak-
ing direct translation impossible. Another possible ex-
planation is that the need for an interpreter is a marker
for major differences in understanding of health, illness
and healing that go beyond the capacity of an inter-
preter to deal with. Alternatively, English-speaking cli-
nicians in a majority English-speaking culture may not




High score a Low score b
N = 22 N = 24
(n) (n)
Age, years 22 24
Interpreter 6 15
I & R Clinic 7 10
Male sex 9 12
Tertiary educated 16 13
Lived in a refugee camp 3 6
Mean number of clinic visits 2.5 2.6
Residence in Australia > 1 year 13 12
Sub-Saharan African country of birth 7 6
I & R Clinic = Immigrant and Refugee Clinic; CI = Confidence Interval; uIRR = unadjus
a High Score, greater than 6/9.
b Low Score, less than or equal to 6/9.Nearly 46% of patients reported missing treatment for
between one and ten days in the prior month, with most
reporting that they had forgotten to take their tablets.
This is a concerning figure with potential impacts on the
effectiveness of treatment. Whilst health education activ-
ities may not improve memory, repeated explanations
about the potential consequences of forgetting may help
to crystallize the importance of good adherence. Fre-
quent clinic visits, for example monthly, may also help
to reinforce these messages and improve adherence.
Newer treatment regimens, such as weekly isoniazid and
rifapentine for 12 weeks, are simpler, may improve adher-
ence and may be suitable for these patients [27]. This regi-
men was not available in Australia at the time of the study.
The study has several potential limitations. The
number of participants was relatively small. Despite
this, there were still some significant results found in
the multivariable regression. Although a standardised
explanation was not provided by physicians, a similar
way of explaining concepts is used by the doctors in
the clinics and there is very little turn-over of doctors.
We cannot be certain, however, whether all concepts
tested on the questionnaires were explained to all pa-
tients. There may also have been a loss of information
accuracy through the use of an interpreter. Further-
more, baseline knowledge of participants was not
tested. The questionnaire utilised was developed spe-
cifically for the purpose of this study and has not been
used within other population groups. Whilst it has face
validity, it may need to be validated in other studies.
Conclusions
This study found that refugee and immigrant patients at-
tending two infectious diseases outpatient clinics at a)
tal knowledge Score- questionnaire 2
le analysis Multivariable analysis
uIRR (95% CI) P aIRR (95% CI) P
1.02 (0.89-1.75) 0.737
0.23 (0.07-0.79) 0.019 0.313 (0.14-0.69) 0.004







ted Incidence Rate Ratio; aIRR = adjusted Incidence Rate Ratio.
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standing and knowledge of latent TB, its treatment regi-
men and treatment side effects. These findings have
significant implications for clinical practice. The associ-
ation between having an interpreter and low knowledge
and understanding is particularly worrying as it suggests
that patients requiring an interpreter may be at a disad-
vantage, for which use of an interpreter is insufficient to
compensate. Medical education programs are needed to
improve interpreters’ knowledge about latent TB (and
other diseases) in order to transfer accurate health mes-
sages to patients. There is currently no specialist training
for interpreters in medical vocabulary and no require-
ment that there should be such training. Any training
that takes place is through self-funded personal develop-
ment. Outsourcing of interpreting services may prevent
the accumulation of organisational experience in the
field or in specific institutions. One possible avenue to
address this deficit is offering certified short courses for
interpreters who work in health care settings. Similarly,
immigrant and refugee populations would benefit from
linguistically and culturally appropriate health education.
This would be particularly beneficial for refugee patients
from non-English speaking backgrounds who may have
low health literacy and limited access to accurate infor-
mation. Information is available in some languages other
than English, but not in the languages most commonly
spoken by our patients. Translation is limited by lack
of resources. Another, more complex response would
be the development of a bilingual health worker role to
provide support and education to individual patients
and ethnic communities beyond simple interpreting.
Findings from this study could help to inform pro-
viders of TB care how best to educate and motivate pa-
tients from very different cultural and linguistic
backgrounds about the importance of adherence to
treatment for latent TB.Additional files
Additional file 1: Survey instrument. This file contains Questionnaire 1
administered to participants. Key sections have been reported in this paper.
Additional file 2: Survey instrument. This file contains Questionnaire 2
administered to participants. Key sections have been reported in this paper.
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